Evidence map›Paper›PMID 27918573›Full record

ReviewPLoS neglected tropical diseases2016

Benchmarking the Cost per Person of Mass Treatment for Selected Neglected Tropical Diseases: An Approach Based on Literature Review and Meta-regression with Web-Based Software Application.

Christopher Fitzpatrick, Fiona M Fleming, Matthew Madin-Warburton, Timm Schneider, Filip Meheus, Kingsley Asiedu, Anthony W Solomon, Antonio Montresor, Gautam Biswas

Open access · goldAbstract readReview
In one paragraph

Review in PLoS neglected tropical diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 4 pooled it
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 4 syntheses or guidelines pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Economic Evaluations of Mass Drug Administration: The Importance of Economies of Scale and Scope.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018
    Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. What are economic costs and when should they be used in health economic studies?Cost effectiveness and resource allocation : C/E · 2023
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 4 countries.

Christopher FitzpatrickDepartment of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland.
Fiona M FlemingImperial College London, London, United Kingdom.
Matthew Madin-WarburtonDepartment of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland.
Timm SchneiderUniversität Düsseldorf, Düsseldorf, Germany.
Filip MeheusHealth Economics Unit, University of Cape Town, Cape Town, South Africa.
Kingsley AsieduDepartment of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland.
Anthony W SolomonDepartment of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland.
Antonio MontresorDepartment of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland.
Gautam BiswasDepartment of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland.
World Health Organization · CHHeinrich Heine University Düsseldorf · DEImperial College London · GBUniversity of Cape Town · ZA

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundAdvocacy around mass treatment for the elimination of selected Neglected Tropical Diseases (NTDs) has typically put the cost per person treated at less than US$ 0.50. Whilst useful for advocacy, the focus on a single number misrepresents the complexity of delivering "free" donated medicines to about a billion people across the world. We perform a literature review and meta-regression of the cost per person per round of mass treatment against NTDs. We develop a web-based software application (https://healthy.shinyapps.io/benchmark/) to calculate setting-specific unit costs against which programme budgets and expenditures or results-based pay-outs can be benchmarked.

methodsWe reviewed costing studies of mass treatment for the control, elimination or eradication of lymphatic filariasis, schistosomiasis, soil-transmitted helminthiasis, onchocerciasis, trachoma and yaws. These are the main 6 NTDs for which mass treatment is recommended. We extracted financial and economic unit costs, adjusted to a standard definition and base year. We regressed unit costs on the number of people treated and other explanatory variables. Regression results were used to "predict" country-specific unit cost benchmarks.

resultsWe reviewed 56 costing studies and included in the meta-regression 34 studies from 23 countries and 91 sites. Unit costs were found to be very sensitive to economies of scale, and the decision of whether or not to use local volunteers. Financial unit costs are expected to be less than 2015 US$ 0.50 in most countries for programmes that treat 100 thousand people or more. However, for smaller programmes, including those in the "last mile", or those that cannot rely on local volunteers, both economic and financial unit costs are expected to be higher. DISCUSSION: The available evidence confirms that mass treatment offers a low cost public health intervention on the path towards universal health coverage. However, more costing studies focussed on elimination are needed. Unit cost benchmarks can help in monitoring value for money in programme plans, budgets and accounts, or in setting a reasonable pay-out for results-based financing mechanisms.

Indexed as

BenchmarkingHealth Care CostsSoftwareAnthelminticsElephantiasis, FilarialHealth ExpendituresHelminthiasisHumansInternetNeglected DiseasesOnchocerciasisPublic HealthPublic Health PracticeSchistosomiasisTropical ClimateAnthelmintics

Identifiers

PMID27918573
PMCPMC5137870
OpenAlexW2560687040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.